Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...
L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...
A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic ...
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...
“Idiopathic inflammatory myopathies are debilitating diseases that can cause muscle weakness, affect multiple organs, and have a severe impact on patients’ quality of life, including increased ...
Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...
Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback